Skip to main content

Surgical Myectomy and Associated Procedures: Techniques and Outcomes

  • Chapter
  • First Online:
Hypertrophic Cardiomyopathy

Abstract

Patients with HCM and obstructive physiology who remain significantly symptomatic despite optimal medical management are candidates for septal reduction therapy. As surgical septal myectomy has been practiced for over 50 years, with current experience demonstrating excellent short- and long-term survival and minimal complications in experienced centers, this surgery has become the gold standard technique for relief of obstruction. Echocardiographic intraprocedural guidance is essential, as well as a team approach. Novel techniques and approaches continue to evolve to tackle more complex manifestations of the disease involving the mitral valve, apex, or mid-cavity, inclusive of papillary muscle abnormalities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AF:

Atrial fibrillation

ASA:

Alcohol septal ablation

CABG:

Coronary artery bypass grafting

CAD:

Coronary artery disease

HCM:

Hypertrophic cardiomyopathy

ICD:

Internal cardiac defibrillator

LV:

Left ventricle

LVOTO:

Left ventricular outflow tract obstruction

MVR:

Mitral valve replacement

NYHA:

New York Heart Association

PPM:

Pacemaker

RPR:

Resection-plication-release

SAM:

Systolic anterior motion

SCD:

Sudden cardiac death

References

  1. Brock R. Functional obstruction of the left ventricle (acquired aortic subvalvular stenosis). Guys Hosp Rep. 1957;106:221–38.

    CAS  PubMed  Google Scholar 

  2. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bertin. Hypertrophy of the left ventricle, with contraction of its cavity. Traite des Maladies du Coeur et des Gros Vaisseaux. 1839.

    Google Scholar 

  4. Schmincke A. Narrowing of left ventricular outflow (Ueber linkseitige muskulose Conus-stenosen). Dtsch Med Wochenschr. 1907;33:2082–3.

    Article  Google Scholar 

  5. Chevers N. Observations on the diseases of the orifice and valves of the aorta. Guys Hosp Rep. 1842;7:387.

    Google Scholar 

  6. Cleland WP. The surgical management of obstructive cardiomyopathy. J Cardiovasc Surg. 1963;4:489–91.

    CAS  Google Scholar 

  7. Van de Wall E, van der Heide JN H. Treatment of hypertrophic obstructive cardiomyopathy by septectomy. Hypertrophic obstructive cardiomyopathy, Wolstenholme GEW. Ciba Found Study Group. 1971;37:160–82.

    Google Scholar 

  8. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation. 1975;52(1):88–102.

    Article  CAS  PubMed  Google Scholar 

  9. Cooley DA, Leachman RD, Wukasch DC. Mitral valve replacement for idiopathic hypertrophic cardiomyopathy. J Cardiovasc Surg. 1976;17:380–7.

    CAS  Google Scholar 

  10. Kracjer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy: 10-year follow-up in 185 patients. Circulation. 1989;80(suppl II):II-57.

    Google Scholar 

  11. McIntosh CL, Greenberg GJ, Maron BJ, Leon MB, Cannon RO 3rd, Clark RE. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 1989;47(2):236–46.

    Article  CAS  PubMed  Google Scholar 

  12. McIntosh CL, Maron BJ, Cannon RO III, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1992;86(suppl II):1160–7.

    Google Scholar 

  13. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85(5):1651–60.

    Article  CAS  PubMed  Google Scholar 

  14. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87:1570–9.

    Article  CAS  PubMed  Google Scholar 

  15. Messmer B. Extended myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 1994;58:575–7.

    Article  CAS  PubMed  Google Scholar 

  16. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92(suppl II):112–27.

    Google Scholar 

  17. Joyce FS, Lever HM, Cosgrove DM. Treatment of hypertrophic cardiomyopathy by mitral valve repair and septal myectomy. Ann Thorac Surg. 1994;57:1025–7.

    Article  CAS  PubMed  Google Scholar 

  18. Sherrid MV, Chaudhry FA, Swistel DG. Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. Ann Thorac Surg. 2003;75:620–32.

    Article  PubMed  Google Scholar 

  19. Swistel DG, DeRose JJ Jr, Sherrid MV. Management of patients with complex hypertrophic cardiomyopathy: resection/plication/release. Oper Tech Thorac Cardiovasc Surg. 2004;9:261–7.

    Article  Google Scholar 

  20. Bhudia SK, McCarthy PM, Smedira NG, Lam BK, Rajeswaran J, Blackstone EH. Edge-to-edge (Alfieri) mitral repair: results in diverse clinical settings. Ann Thorac Surg. 2004;77(5):1598–606.

    Article  PubMed  Google Scholar 

  21. Van der Lee C, Kofflard MJM, van Herwerden LA, Vletter WB, ten Cate FJ. Sustained improvement after combined mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation. 2003;108:2088–92.

    Article  PubMed  Google Scholar 

  22. Dearani JA, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy. Oper Tech Thorac Cardiovasc Surg. 2004;9:278–92.

    Article  Google Scholar 

  23. Delmo Walter EM, Siniawski H, Hetzer R. Sustained improvement after combined anterior mitral valve leaflet retention plasty and septal myectomy in preventing systolic anterior motion in hypertrophic obstructive cardiomyopathy in children. Eur J Cardiothorac Surg. 2009;36:546–52.

    Article  PubMed  Google Scholar 

  24. Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, Desai MY. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg. 2010;140(2):317–24.

    Article  PubMed  Google Scholar 

  25. Swistel DG, Balaram SK. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the “RPR” repair: resection, plication, and release. Prog Cardiovasc Dis. 2012;54:498–502.

    Article  PubMed  Google Scholar 

  26. Balaram SK, Sherrid MV, Derose JJ Jr, Hillel Z, Winson G, Swistel DG. Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair. Ann Thorac Surg. 2005;80(1):217–23.

    Article  PubMed  Google Scholar 

  27. Balaram SK, Tyrie L, Sherrid MV, Afthinos J, Hillel Z, et al. Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. Ann Thorac Surg. 2008;86(5):1539–44.

    Article  PubMed  Google Scholar 

  28. Balaram SK, Ross RE, Sherrid MV, Schwartz GS, Hillel Z, Winson G, Swistel DG. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. Ann Thorac Surg. 2012;94(6):1990–7. discussion 1997–8

    Article  PubMed  Google Scholar 

  29. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation. 1988;78(3):487–95.

    Article  CAS  PubMed  Google Scholar 

  30. Schaff HV, Brown ML, Dearani JA, Abel MD, Ommen SR, et al. Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2010;139:634–40.

    Article  PubMed  Google Scholar 

  31. Said SM, Schaff HV, Able MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg. 2012;27(4):443–8.

    Article  PubMed  Google Scholar 

  32. Said SM, Dearani JA, Ommen SR, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2013;11(5):617–27.

    Article  CAS  PubMed  Google Scholar 

  33. Kunkala MR, Schaff HV, Nishiura RA, Abel MD, Sorajja P, Dearani JA, Ommen SR. Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. Ann Thorac Surg. 2013;96(2):564–70.

    Article  PubMed  Google Scholar 

  34. Kaple RK, Murphy RT, DePaola LM, Houghtaling PL, Lever HM, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85:1527–36.

    Article  PubMed  Google Scholar 

  35. Wan CKN, Dearani JA, Sundt TM, Ommen SR, Schaff HV. What is the best surgical treatment for obstructive hypertrophic cardiomyopathy and degenerative mitral regurgitation? Ann Thorac Surg. 2009;88:727–32.

    Article  PubMed  Google Scholar 

  36. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687–713.

    Article  PubMed  Google Scholar 

  37. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783–831.

    PubMed  Google Scholar 

  38. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308–20.

    Article  PubMed  Google Scholar 

  39. Sherrid MV. Dynamic left ventricular outflow obstruction in hypertrophic cardiomyopathy revisited: significance, pathogenesis, and treatment. Cardiol Rev. 1998;6(3):135–45.

    Article  CAS  PubMed  Google Scholar 

  40. Sherrid M, Barac I. Pharmacologic treatment of symptomatic hypertrophic cardiomyopathy. In: Maron FJ, editor. Diagnosis and management of hypertrophic cardiomyopathy. Boston: Blackwell-Futura; 2004. p. 200–19.

    Chapter  Google Scholar 

  41. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281(7):650–5.

    Article  CAS  PubMed  Google Scholar 

  42. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, et al. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: experience over 15 years. J Thorac Cardiovasc Surg. 1989;97(5):666–74.

    CAS  PubMed  Google Scholar 

  43. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy. Thorac Cardiovasc Surg. 1999;47:213–8.

    Article  CAS  PubMed  Google Scholar 

  44. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg. 1995;110(1):195–206. discussion 206–8

    Article  CAS  PubMed  Google Scholar 

  45. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111(3):586–94.

    Article  CAS  PubMed  Google Scholar 

  46. Schonbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg. 1998;65(5):1207–14.

    Article  CAS  PubMed  Google Scholar 

  47. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–6.

    Article  PubMed  Google Scholar 

  48. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111(16):2033–41.

    Article  PubMed  Google Scholar 

  49. Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathy- the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4(9):503–12.

    Article  PubMed  Google Scholar 

  50. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85(1):127–33.

    Article  PubMed  Google Scholar 

  51. Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, Lever HM. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–16.

    Article  CAS  PubMed  Google Scholar 

  52. Maron BJ, Ommen SR, Nishimura RA, Dearani JA. Myths about surgical myectomy: rumors of its death have been greatly exaggerated. Am J Cardiol. 2008;101(6):887–9.

    Article  PubMed  Google Scholar 

  53. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:2044–53.

    Article  PubMed  Google Scholar 

  54. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):480–7.

    Article  PubMed  Google Scholar 

  55. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108(19):2342–8.

    Article  PubMed  Google Scholar 

  56. Minami K, Boethig D, Woltersdorf H, Seifert D, Körfer R. Long term follow-up of surgical treatment of hypertrophic obstructive cardiomyopathy (HOCM): the role of concomitant cardiac procedures. Eur J Cardiothorac Surg. 2002;22(2):206–1.

    Article  PubMed  Google Scholar 

  57. Autore C, Bernabò P, Barillà CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45(7):1076–80.

    Article  PubMed  Google Scholar 

  58. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.

    Article  PubMed  Google Scholar 

  59. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92:1680–169.

    Article  CAS  PubMed  Google Scholar 

  60. Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004;350:1320–7.

    Article  CAS  PubMed  Google Scholar 

  61. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985;28:1–83.

    Article  CAS  PubMed  Google Scholar 

  62. Watson DC, Henry WL, Epstein SE, Morrow AG. Effects of operation on left atrial size and the occurrence of atrial fibrillation in patients with hypertrophic subaortic stenosis. Circulation. 1977;55:178–81.

    Article  CAS  PubMed  Google Scholar 

  63. Roberts CS, Gertz SD, Klues HG, Cannon RO 3rd, Maron BJ, McIntosh CL, Roberts WC. Appearance of or persistence of severe mitral regurgitation without left ventricular outflow obstruction after partial ventricular septal myotomy-myectomy in hypertrophic cardiomyopathy. Am J Cardiol. 1991;68(17):1726–8.

    Article  CAS  PubMed  Google Scholar 

  64. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36(7):2219–25.

    Article  CAS  PubMed  Google Scholar 

  65. Sherrid MV, Chu CK, Delia E, Mogtader A, Dwyer EM Jr. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22(3):816–25.

    Article  CAS  PubMed  Google Scholar 

  66. Shah PM, Gramiak R, Adelman AG, Wigle ED. Echocardiographic assessment of the effects of surgery and propranolol on the dynamics of outflow obstruction in hypertrophic subaortic stenosis. Circulation. 1972;45:516–21.

    Article  CAS  PubMed  Google Scholar 

  67. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation. 1991;84(3):1188–97.

    Article  CAS  PubMed  Google Scholar 

  68. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47(3):532–8.

    Article  CAS  PubMed  Google Scholar 

  69. Shah PM, Adelman AG, Wigle ED, Gobel FL, Burchell HB, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res. 1974;35(2):suppl II:179–95.

    Google Scholar 

  70. Arteaga E, Ianni BM, Fernandes F, Mady C. Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil. Am Heart J. 2005;149(6):1099–105.

    Article  PubMed  Google Scholar 

  71. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320(12):749–55.

    Article  CAS  PubMed  Google Scholar 

  72. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27(16):1933–41.

    Article  PubMed  Google Scholar 

  73. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.

    Article  PubMed  Google Scholar 

  74. Sherrid MV, Wever-Pinzon O, Shah A, Chaudhry FA. Reflections of inflections in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(3):212–9.

    Article  PubMed  Google Scholar 

  75. Woo A, Rakowski H. Does myectomy convey survival benefit in hypertrophic cardiomyopathy? Heart Fail Clin. 2007;3(3):275–88.

    Article  PubMed  Google Scholar 

  76. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212–8.

    Article  CAS  PubMed  Google Scholar 

  77. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28(21):2583–8.

    Article  PubMed  Google Scholar 

  78. Minakata K, Dearani JA, Schaff HV, O'Leary PW, Ommen SR, Danielson GK. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 2005;80(3):851–6.

    Article  PubMed  Google Scholar 

  79. El Bardissi AW, Dearani JA, Nishimura RA, Ommen SR, Stulak JM, Schaff HV. Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy. Mayo Clin Proc. 2007;82(12):1516–22.

    Article  Google Scholar 

  80. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15(6):1279–85.

    Article  CAS  PubMed  Google Scholar 

  81. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.

    Article  CAS  PubMed  Google Scholar 

  82. Olivotto I, Maron BJ, Cecchi F. Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. Curr Cardiol Rep. 2001;3(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  83. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003;42(5):882–8.

    Article  PubMed  Google Scholar 

  84. Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR, Casazza F, Galderisi M, Maron BJ, Cecchi F. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol. 2006;98(7):960–5.

    Article  PubMed  Google Scholar 

  85. Chen MS, McCarthy PM, Lever HM, Smedira NG, Lytle BL. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(3):373–5.

    Article  PubMed  Google Scholar 

  86. Watson DC, Henry WL, Epstein SE, Morrow AG. Effects of operation on left atrial size and the occurence of atrial fibrillation in patients with hypertrophic subaortic stenosis. Circulation. 1977;55(1):178–81.

    Article  CAS  PubMed  Google Scholar 

  87. Cavalcante JL, Barboza JS, Lever HM. Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54(6):517–22.

    Article  PubMed  Google Scholar 

  88. Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C, Pentiricci S, Poggio D, Grillo M, Amigoni P. Transaortic chordal cutting. JACC. 2015;66(15):1687–96.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel G. Swistel .

Editor information

Editors and Affiliations

Questions

Questions

  1. 1.

    A 60-year-old man undergoes an uneventful septal myectomy and requires pacing while separating from bypass. The following day he is found to have third-degree heart block. What preoperative factor confers the highest risk for permanent pacemaker after septal myectomy?

    1. A.

      AICD placement within 6 months prior to surgery

    2. B.

      Septal thickness less than 20 mm on transesophageal echocardiogram

    3. C.

      Right bundle-branch block on ECG

    4. D.

      Paroxysmal atrial fibrillation

    5. E.

      Family history of HOCM associated sudden death

    Answer: C. The incidence of permanent pacemaker requirement after septal myectomy is about 2–3%. In patients with relatively modest septal thickening, it may be advantageous to resect a shallow but broader segment of septum and even some posterior septum. That may predispose to complete heart block. However, since left bundle-branch block is almost always a consequence of septal myectomy, if the patient has a pre-existing right bundle-branch block, complete heart block and a requirement for a permanent pacemaker is almost a certainty.

  2. 2.

    A 54-year-old woman with LVOT gradient of 60 mmHg and septal thickness of 1.9 cm undergoes septal myectomy and resection of excess tissue at the base of her anterolateral papillary muscle. While separating from bypass, TEE demonstrates a significant left to right shunt. What is the most likely site of injury ?

    1. A.

      The distal point of septal resection

    2. B.

      Below the right coronary cusp of the aortic annulus

    3. C.

      Base of the anterolateral papillary muscle

    4. D.

      Proximal aspect of myectomy along the anterior leaflet of mitral valve

    5. E.

      Posterior septum at attachment to free left ventricular wall

    Answer: B. Although it is possible to disrupt the ventricular wall with resection of muscle at the base of the anterolateral papillary muscle, that would lead to a free wall rupture into the pericardium. On the other hand, if the septum is minimally thickened and a broader myectomy is performed, it may extend into the membranous portion of the septum under the right coronary leaflet which is invariably very thin. This is the most common location for a VSD.

  3. 3.

    A 58-year-old man arrives in the recovery room following septal myectomy and has a new left bundle-branch block with heart rate 70 and blood pressure 90/40 mmHg, CVP 5, PA 25/15, and cardiac index 1.6. What is the best approach to initial management ?

    1. A.

      Contact electrophysiology for urgent permanent pacemaker.

    2. B.

      Bedside echocardiogram to assess for ventricular septal defect.

    3. C.

      Initiate inotropic support with dobutamine.

    4. D.

      Trial of pacing via temporary wires at rate of 90.

    5. E.

      Administer 1 L crystalloid and initiate phenylephrine drip.

    Answer: E. Patients with HCM suffer with varying degrees of diastolic dysfunction due to myocardial fibrosis. It is not uncommon to have a low cardiac output state in the immediate post-op period. It is critical not to administer any inotropic support as this will further limit ventricular filling. Likewise, pacing at a faster rate would have the same effect. The PA pressure is too low to be consistent with a VSD. These patients almost invariably require higher filling pressures, especially in the immediate post-op period.

  4. 4.

    A 54-year-old woman with history of persistent atrial fibrillation and left atrial diameter of 52 mm and septal thickness of 20 mm. Which of the following is not a risk factor for mortality after isolated septal myectomy?

    1. A.

      Female gender

    2. B.

      Age 54

    3. C.

      Preoperative atrial fibrillation

    4. D.

      LA diameter 52 mm

    5. E.

      Septal thickness 20 mm

    Answer: E. Age, gender, and atrial fibrillation are all risk factors for mortality in open-heart surgery in general. A dilated left atrium is usually the consequence of the atrial fibrillation. Although modest septal thickening may seem like a risk factor for creation of a VSD, that has not been shown to be true.

  5. 5.

    Which of the following best describes the role of AICD for patients undergoing septal myectomy?

    1. A.

      AICD placement is recommended in all patients with EF <60% at time of septal myectomy.

    2. B.

      After septal myectomy, AICD firing rate decreases to <0.5% per year.

    3. C.

      Septal myectomy obviates the need for subsequent AICD placement.

    4. D.

      Most AICD should be explanted at time of septal myectomy.

    5. E.

      Patients with preoperative AICD have a threefold increase in the risk of postoperative VSD complicating septal myectomy.

    Answer: B. The need for AICD in patients with HCM is decided by predetermined criteria. Recent follow-up information would suggest that although there is a decrease in the firing of an AICD after a properly performed surgical myectomy, because myocardial fiber disarray persists in the remainder of the muscle, ventricular tachyarrhythmias can still occur with deadly consequences. Therefore, the current recommendation is to keep the AICD in these patients who fulfill criteria for their original implantation. A LVEF of <60% is not criteria, and there is no relationship between AICD placement and subsequent VSD.

  6. 6.

    A 60-year-old man with LVOT gradient of 60 mmHg, septal thickness of 26 mm, and class III heart failure undergoes septal myectomy. Five years later he is seen in follow-up with an LVOT gradient of 15 mmHg and class I heart failure. Which of the following is not an expected long-term benefit following septal myectomy compared to medical treatment?

    1. A.

      Decreased risk of atrial fibrillation and left atrial size

    2. B.

      Decrease in risk of sudden death to age- and sex-matched controls

    3. C.

      Improvement in functional heart failure class

    4. D.

      LVOT gradient <30 mmHg

    5. E.

      Improved survival compared to asymptomatic or minimally symptomatic HOCM patients

    Answer: B. A properly performed septal myectomy with resolution of a resting and provocable gradient to near normal gives the patient a normal life expectancy. It would not improve the life expectancy beyond age- and gender-matched controls, nor would it eliminate the risk of sudden death from a ventricular tachyarrhythmia. That risk does, however, match a control population.

  7. 7.

    A 39-year-old woman undergoes septal myectomy and plication of the anterior leaflet of her mitral valve for LVOT gradient of 65 mmHg with septal thickness of 24 mm. A TEE is performed during weaning from bypass. Which of the following scenarios would be the least likely to prompt further investigation?

    1. A.

      New onset mild tricuspid regurgitation

    2. B.

      Inotrope-provoked gradient of 30 mmHg

    3. C.

      Turbulent LVOT flow

    4. D.

      2+ mitral regurgitation

    5. E.

      Left to right shunt at level of midventricular septum

    Answer: A. After septal myectomy, there should no longer be a resting or provocable gradient above 20 mmHg. Mitral insufficiency should also not be tolerated since that would be a consequence of either an inadequate operation or damage to the supporting mitral valve substructure. A VSD would also not be tolerated. Mild tricuspid insufficiency, on the other hand, may be a consequence of some RV dysfunction secondary to heart-lung bypass and usually is self-limiting in the postoperative period.

  8. 8.

    Which of the following is correct regarding anterior mitral leaflet plication during septal myectomy?

    1. A.

      Most successful when redundant anterior leaflet height is less 20 mm in length.

    2. B.

      Vertical plication is more technically challenging but allowed for greater reduction in postoperative SAM.

    3. C.

      Horizontal plication preserves the zone of coaptation between leaflets.

    4. D.

      Easiest to perform prior to distortion of anatomy resulting from septal myectomy.

    5. E.

      Contraindicated in patients undergoing concomitant coronary artery bypass grafting.

    Answer: C. Although vertical plication has been described to be a useful tool in the surgical treatment of HCM, it has also been found to cause central mitral regurgitation in some cases due to malcoaptation of the leaflets. Horizontal plication is most easily accomplished after the myectomy, since visualization in the LV chamber is greatly improved. The anterior leaflet is usually in excess of 3.5 cm in length in cases where plication would be useful.

  9. 9.

    A 58-year-old man has severe midventricular obstruction from septal hypertrophy. Which of the following is correct regarding approach to this lesion?

    1. A.

      Apical myotomy is a useful approach in patients with apical aneurysm.

    2. B.

      Using a ventriculotomy approach, the septal wall can easily be distinguished from papillary muscles by identifying cordal attachments.

    3. C.

      Midventricular obstruction cannot be fully resected via aortotomy.

    4. D.

      Multiple layers of septal resection allows for the most accurate depth of resection.

    5. E.

      Successful resection of midventricular hypertrophy prevents SAM without the need for additional mitral intervention.

    Answer: A. Although it is possible, it can be extremely challenging to resect adequate septal muscle in cases of midventricular obstruction through an aortotomy. If an apical aneurysm is present, it is helpful to approach these resections from both the apex and the aortotomy. In the approach through the apex, unless the aneurysm is very large, differentiating the septum from hypertrophied papillary muscle can be difficult. It is useful to do as much of a resection as possible through the aortotomy, then open the apex, and locate the site of resection and complete it apically. In general, patients with midventricular obstruction do not have SAM.

  10. 10.

    Which of the following patients would least likely benefit for septal myectomy?

    1. A.

      A 50-year-old man with resting gradient 48 mmHg and recurrent syncope on disopyramide

    2. B.

      A 60-year-old man with provoked gradient of 45 mmHg and resolution of chest pain on verapamil

    3. C.

      A 72-year-old woman with provoked gradient of 55 mmHg and persistent dyspnea on metoprolol

    4. D.

      A 26-year-old woman with exercise intolerance and resting gradient of 50 mmHg

    5. E.

      A 45-year-old man on verapamil with intermittent chest pain that resolves with rest and a provoked gradient of 60 mmHg

    Answer: B. Patients undergoing surgical management for HCM must fulfill certain criteria. They must have a resting or provocable gradient of at least 50 mmHg, and they must be symptomatic. Control of symptoms and gradient with medication is not an indication for surgical management.

  11. 11.

    Known mitral valve anomalies in HCM do not include:

    1. A.

      Anomalous papillary muscles

    2. B.

      Elongated anterior mitral leaflet

    3. C.

      Elongated posterior mitral leaflet

    4. D.

      Thickened or fibrotic leaflets

    5. E.

      Cleft leaflets

    Answer: E. A wide variety of mitral valve abnormalities can be present along with septal hypertrophy that can contribute to obstruction. Although some advocate for minimizing mitral valve manipulation in the surgical treatment of obstruction, some patients have such minimal septal hypertrophy that without addressing the mitral valve pathologies, obstruction and mitral regurgitation are likely to persist to a significant degree. Cleft leaflets, however, are not part of this pathology.

  12. 12.

    The “extended myectomy ” includes all of the features except:

    1. A.

      Wide resection of the basal septum

    2. B.

      Shaving of papillary muscle heads

    3. C.

      Removal of lateral attachments

    4. D.

      Transaortic exposure

    5. E.

      Simple trough-like removal of septum

    Answer: E. The classic “morrow” myectomy traditionally consists of a trough resection roughly 1 cm wide, 1 cm deep, and about 3–4 cm long. As our understanding of the pathophysiology of obstruction has progressed, it is clear that a large proportion of patients require a wider and more extensive resection in order to allow for a more linear stream of outflow, thereby minimizing the risk of the “pushing force of flow” that catches the anterior leaflet of the mitral valve and propels it into the outflow tract.

  13. 13.

    Absolute indications for surgery for HCM include:

    1. A.

      Enlarged LA and atrial fibrillation

    2. B.

      Persistent symptoms despite maximal medical therapy

    3. C.

      Gradient >30 mmHg

    4. D.

      Severe mitral regurgitation

    5. E.

      Moderate aortic insufficiency

    Answer: B. There are clear published indications for surgical management of outflow tract obstruction in the treatment of hypertrophic cardiomyopathy. There must be a gradient, either at rest or on provocation of >50 mmHg, and symptoms.

  14. 14.

    Absolute proven benefits of septal myectomy include:

    1. A.

      Improved quality of life

    2. B.

      Improved ejection fraction

    3. C.

      Prevention of arrhythmias

    4. D.

      Better long-term survival

    5. E.

      Prevention of sudden death

    Answer: A. Although mid- to long-term follow-up would suggest that a well-performed surgical septal myectomy dramatically lowers the risk of sudden death, because muscle fiber disarray persists in the rest of the unresected myocardium, a risk of sudden death persists. These patients, in general, all have normal ejection fractions already, and unless a concomitant ablation procedure is indicated and performed, septal myectomy on its own does not limit atrial fibrillation.

  15. 15.

    The most common complication after myectomy surgery is:

    1. A.

      Death

    2. B.

      VSD

    3. C.

      Pacemaker

    4. D.

      Atrial fib

    5. E.

      Stroke

    Answer: D. The risk of permanent pacemaker implantation after septal myectomy varies from 2% to 5% in published reports. Death, stroke, and VSD are extremely rare when myectomy is performed in referral center programs with large volumes. Atrial fibrillation occurs after septal myectomy in roughly the same incidence as any other open-heart surgical procedure – anywhere from 20% to 45%.

  16. 16.

    Common acceptable medications to be used after myectomy for HCM include:

    1. A.

      Beta-blockers

    2. B.

      Epinephrine

    3. C.

      Norepinephrine

    4. D.

      Dobutamine

    5. E.

      Milrinone

    Answer: A. As these patients already have a degree of diastolic dysfunction from varying amounts of fibrosis and since the ejection fraction is almost always hyperdynamic, any inotrope (epinephrine, norepinephrine, dobutamine) administered in the immediate postoperative period would further limit ventricular filling and cardiac output. The same would be true for a peripheral vasodilating medication (milrinone) which would reduce afterload and promote ventricular emptying. Beta-blockade is usually always necessary after myectomy surgery both to improve ventricular relaxation and limit postoperative atrial fibrillation which tends to be poorly tolerated by HCM patients.

  17. 17.

    Surgical options in the presence of abnormal papillary muscles include:

    1. A.

      Resection

    2. B.

      Thinning

    3. C.

      Repositioning within the left ventricle

    4. D.

      Replacement of chordae

    5. E.

      Cutting of chordae

    Answer: A. Although a great deal of procedures have been described to aid in moving the anterior leaflet of the mitral valve out of the outflow tract, the papillary muscles themselves cannot be completely resected without ultimately causing prolapse. Accessory attachments, however, can be considered for resection if there are other supporting structures.

  18. 18.

    The main difference between the lateral and horizontal plication of the AML is:

    1. A.

      Number of stitches

    2. B.

      Location of stiches

    3. C.

      Shortening of the leaflet

    4. D.

      Postop MR

    5. E.

      Long-term changes to the valve

    Answer: C. Both lateral and horizontal plication have been described as successful ancillary procedures to help in gradient reduction in HCM surgery. Whereas lateral plication is thought to limit billowing into the outflow tract, horizontal plication both limits billowing and also shortens the leaflet in the A/P dimension, further limiting the leaflets’ ability to have SAM and subsequent obstruction. The number of stiches and location are inconsistent in both cases.

  19. 19.

    All of the following are related to transmitral resection techniques except:

    1. A.

      Can be done minimally invasively

    2. B.

      Require AML dislocation and resewing

    3. C.

      Risk long-term changes to AML

    4. D.

      Provide exposure to septum

    5. E.

      Can cause aortic insufficiency

    Answer: E. Some have advocated transmitral access to the septum for myectomy and in small series published to date have shown good results. Others have not adopted this approach because septal access is relatively limited, and the current extended myectomy would be somewhat limited as a consequence. Additionally, this procedure requires dislocation of the entire anterior mitral leaflet. This has apparently not been a problem in short-term follow-up. However, given the relative young age of most patients, the concern remains that there may be long-term sequelae to this degree of manipulation of the AML. Since there is no transaortic access, there should not be any complications with the aortic valve in this approach.

  20. 20.

    Large retrospective studies have suggested that risk factors for HCM surgery include all of the following except:

    1. A.

      Women

    2. B.

      Age > 50

    3. C.

      Atrial fibrillation

    4. D.

      Concomitant surgery

    5. E.

      Mitral regurgitation

    Answer: E. As is known in most other open-heart procedures, age, female gender, multiple procedures, and atrial fibrillation all increase the risk of surgery. Since almost all of these patients (HCM) have mitral insufficiency, that would not be an additive risk factor.

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Swistel, D.G., Schubmehl, H., Balaram, S.K. (2019). Surgical Myectomy and Associated Procedures: Techniques and Outcomes. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, Cham. https://doi.org/10.1007/978-3-319-92423-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92423-6_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92422-9

  • Online ISBN: 978-3-319-92423-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics